Pharmaceuticals company Syncom Formulation (India) announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: The company recorded a revenue of Rs 12,552.64 lakh in Q1FY27, representing a YoY increase of 7.38% from Rs 11,690.17 lakh in Q1FY26 and a QoQ decrease of 7.30% from Rs 13,541.18 lakh in Q4FY26. Total Income: Total income for the quarter stood at Rs 13,335.58 lakh, compared to Rs 12,293.64 lakh in Q1FY26 (up 8.48% YoY) and Rs 14,996.56 lakh in Q4FY26 (down 11.08% QoQ). Profit Before Tax (PBT): PBT reached Rs 3,225.22 lakh in Q1FY27, registering a significant YoY growth of 58.94% from Rs 2,029.24 lakh in Q1FY26, while recording a QoQ decline of 4.30% from Rs 3,370.26 lakh in Q4FY26. Net Profit: Profit for the period was reported at Rs 2,484.68 lakh, showing a YoY increase of 57.71% from Rs 1,575.44 lakh in Q1FY26 and a slight QoQ decrease of 1.30% from Rs 2,517.44 lakh in Q4FY26. Earnings Per Share (EPS): Basic and Diluted EPS for Q1FY27 was Rs 0.26, compared to Rs 0.17 in Q1FY26 and Rs 0.27 in Q4FY26. Standalone Financial Highlights: Revenue from Operations: For Q1FY27, standalone revenue stood at Rs 12,465.95 lakh, a YoY increase of 6.96% from Rs 11,654.69 lakh in Q1FY26 and a QoQ decline of 6.97% from Rs 13,400.03 lakh in Q4FY26. Total Income: Standalone total income for the quarter reached Rs 13,247.75 lakh, up 8.09% YoY from Rs 12,256.66 lakh in Q1FY26 and down 10.63% QoQ from Rs 14,822.86 lakh in Q4FY26. Profit Before Tax (PBT): Standalone PBT was Rs 3,190.88 lakh, reflecting a YoY growth of 57.51% from Rs 2,025.83 lakh in Q1FY26 and a QoQ decrease of 2.90% compared to Rs 3,286.11 lakh in Q4FY26. Net Profit: Standalone profit for the period reached Rs 2,458.92 lakh, up 56.33% YoY from Rs 1,572.93 lakh in Q1FY26 and showing a marginal QoQ increase of 0.06% from Rs 2,457.42 lakh in Q4FY26. Earnings Per Share (EPS): Basic and Diluted EPS for the quarter was reported at Rs 0.26, compared to Rs 0.17 in Q1FY26 and Rs 0.26 in Q4FY26. Business Highlights: Segment Performance: Pharmaceuticals Drugs & Formulations: Recorded revenue of Rs 13,223.61 lakh in Q1FY27 compared to Rs 12,099.95 lakh in Q1FY26. Segment profit before tax and interest stood at Rs 3,170.25 lakh, up from Rs 1,969.85 lakh in Q1FY26. Trading of Commodities: This segment recorded revenue of Rs 27.84 lakh in Q1FY27, compared to Rs 104.56 lakh in Q1FY26. Segment profit was Rs 1.99 lakh compared to Rs 1.35 lakh in Q1FY26. Renting of Property: Generated revenue of Rs 84.13 lakh in Q1FY27, down from Rs 89.13 lakh in Q1FY26. Segment profit reached Rs 77.43 lakh compared to Rs 83.12 lakh in Q1FY26. Subsidiary Details: The company currently has three wholly owned subsidiaries: Synmex Pharma Pvt Ltd, Vincit Pharma Pvt Limited, and Sante Biotech Pvt Ltd. Accounting Policy Revision: During the current period, the company corrected its method for calculating Earnings Per Share (EPS). Previously calculated considering Total Comprehensive Income, EPS is now computed using Profit After Tax attributable to equity shareholders to comply with Ind AS 33. All comparative EPS figures for preceding periods have been restated accordingly. Result PDF
Pharmaceuticals company Syncom Formulation (India) announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: Consolidated revenue for Q4FY26 was Rs 13,541.18 lakh, a YoY decrease of 9.04% compared to Rs 14,887.64 lakh and a QoQ increase of 17.61% from Rs 11,514.06 lakh. For the full year FY26, revenue increased by 5.19% to Rs 48,917.15 lakh. Total Income: Consolidated total income for Q4FY26 stood at Rs 14,996.56 lakh, down 3.76% YoY and up 24.31% QoQ. For FY26, total income reached Rs 52,051.14 lakh, up 7.89% YoY. Profit Before Tax (PBT): Consolidated PBT for Q4FY26 was Rs 3,370.26 lakh, marking a growth of 44.65% YoY and 34.34% QoQ. For the full year FY26, consolidated PBT grew by 54.35% to Rs 10,111.95 lakh. Net Profit: Net profit for Q4FY26 reached Rs 2,517.44 lakh, representing a YoY growth of 42.27% and a QoQ increase of 33.14%. Consolidated net profit for FY26 stood at Rs 7,643.80 lakh, an increase of 54.62% YoY. Standalone Financial Highlights: Revenue from Operations: For Q4FY26, the company reported revenue of Rs 13,400.03 lakh, representing a YoY decrease of 9.74% from Rs 14,846.33 lakh in Q4FY25 and a QoQ increase of 16.94% from Rs 11,459.05 lakh in Q3FY26. For the full year FY26, revenue stood at Rs 48,657.28 lakh, a growth of 5.13% compared to Rs 46,284.93 lakh in FY25. Total Income: Total income for Q4FY26 was Rs 14,822.86 lakh, a YoY decline of 4.59% from Rs 15,536.64 lakh but a QoQ increase of 23.45% from Rs 12,007.44 lakh. Yearly total income grew by 7.81% to Rs 51,753.91 lakh in FY26. Profit Before Tax (PBT): PBT for Q4FY26 stood at Rs 3,286.11 lakh, up 42.83% YoY from Rs 2,300.77 lakh and up 31.19% QoQ from Rs 2,504.82 lakh. For FY26, standalone PBT reached Rs 10,052.51 lakh, showing a substantial growth of 55.47% YoY. Net Profit: The company recorded a standalone net profit of Rs 2,457.42 lakh in Q4FY26, registering a YoY growth of 40.41% from Rs 1,750.20 lakh and a QoQ increase of 30.27% from Rs 1,886.34 lakh. Yearly net profit for FY26 was Rs 7,600.80 lakh, up 55.53% from Rs 4,887.18 lakh in FY25. Business Highlights: Segment-wise Performance (Consolidated FY26): Pharmaceuticals Drugs & Formulations: This primary segment recorded revenue of Rs 51,573.38 lakh for FY26 compared to Rs 47,027.33 lakh in FY25. Segment results (profit before tax and interest) reached Rs 9,931.87 lakh for the year. Trading of Commodities: Segment revenue was Rs 110.03 lakh in FY26, a significant decline from Rs 825.84 lakh in FY25. The segment reported a loss of Rs 2.63 lakh for the year. Renting of Property: This segment generated revenue of Rs 367.73 lakh in FY26, with a segment profit of Rs 298.21 lakh. Subsidiaries: The Company currently has 3 Wholly Owned Subsidiaries, namely Synmex Pharma Pvt. Ltd., Sante Biotech Pvt. Ltd., and Vincit Biotech International Pvt. Ltd. Impact of New Labour Codes: The Company has assessed the implications of the New Labour Codes and recognized an incremental cost of Rs 87.81 lakh during the year ended March 31, 2026. Correction in EPS Calculation: During the current period, the company corrected its method of calculating Earnings Per Share (EPS) to comply with Ind AS 33. EPS is now computed using Profit After Tax attributable to equity shareholders instead of Total Comprehensive Income. Accordingly, comparative EPS figures for preceding periods have been restated. Result PDF
Pharmaceuticals company Syncom Formulation (India) announced Q3FY26 results Revenue from operations: Rs 11,544.06 lakh against Rs 12,753.32 lakh during Q3FY25, change -9%. PBT: Rs 2,608.8 lakh against Rs 1,726.22 lakh during Q3FY25, change 51%. PAT: Rs 1,890.81 lakh against Rs 1,300.2 lakh during Q3FY25, change 45%. EPS: Rs 0.23 for Q3FY26. Result PDF